Serum levels of IL-17A in patients with relapsing-remitting multiple sclerosis treated with interferon-Beta

The National MS Society-funded MS Outcome Assessments Consortium (MSOAC) held its first annual meeting with the U.S. Food and Drug Administration on 1-2 April to discuss steps needed to “qualify” a new measure of MS disability that will be recognised by the FDA and the European Medicines Agency to speed new therapies for MS, particularly progressive forms of the disease. 

Click here to read more on the NMSS website